IL325730A - 2-phenoxy-1-(4-(alkylsulfonyl)piperidin-1-yl)ethan-1-one and 3-phenyl-1-(4-(alkylsulfonyl)piperidin-1-yl)prop-2-en-1-one derivatives as gpr183 antagonists for the treatment of chronic pain - Google Patents

2-phenoxy-1-(4-(alkylsulfonyl)piperidin-1-yl)ethan-1-one and 3-phenyl-1-(4-(alkylsulfonyl)piperidin-1-yl)prop-2-en-1-one derivatives as gpr183 antagonists for the treatment of chronic pain

Info

Publication number
IL325730A
IL325730A IL325730A IL32573026A IL325730A IL 325730 A IL325730 A IL 325730A IL 325730 A IL325730 A IL 325730A IL 32573026 A IL32573026 A IL 32573026A IL 325730 A IL325730 A IL 325730A
Authority
IL
Israel
Prior art keywords
piperidin
alkylsulfonyl
gpr183
ethan
prop
Prior art date
Application number
IL325730A
Other languages
Hebrew (he)
Inventor
Marko Ahlmark
Anssi Haikarainen
Ari-Pekka Koivisto
Esa Kumpulainen
Aleksi Sahari
Ainoleena Turku
Emilia Vaisanen
Original Assignee
Orion Corp
Marko Ahlmark
Anssi Haikarainen
Koivisto Ari Pekka
Esa Kumpulainen
Aleksi Sahari
Ainoleena Turku
Emilia Vaisanen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp, Marko Ahlmark, Anssi Haikarainen, Koivisto Ari Pekka, Esa Kumpulainen, Aleksi Sahari, Ainoleena Turku, Emilia Vaisanen filed Critical Orion Corp
Publication of IL325730A publication Critical patent/IL325730A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Immunology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
IL325730A 2023-07-05 2024-07-04 2-phenoxy-1-(4-(alkylsulfonyl)piperidin-1-yl)ethan-1-one and 3-phenyl-1-(4-(alkylsulfonyl)piperidin-1-yl)prop-2-en-1-one derivatives as gpr183 antagonists for the treatment of chronic pain IL325730A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20237131 2023-07-05
PCT/FI2024/050372 WO2025008574A1 (en) 2023-07-05 2024-07-04 2-phenoxy-1-(4-(alkylsulfonyl)piperidin-1-yl)ethan-1-one and 3-phenyl-1-(4-(alkylsulfonyl)piperidin-1-yl)prop-2-en-1-one derivatives as gpr183 antagonists for the treatment of chronic pain

Publications (1)

Publication Number Publication Date
IL325730A true IL325730A (en) 2026-03-01

Family

ID=91950461

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325730A IL325730A (en) 2023-07-05 2024-07-04 2-phenoxy-1-(4-(alkylsulfonyl)piperidin-1-yl)ethan-1-one and 3-phenyl-1-(4-(alkylsulfonyl)piperidin-1-yl)prop-2-en-1-one derivatives as gpr183 antagonists for the treatment of chronic pain

Country Status (11)

Country Link
EP (1) EP4739656A1 (en)
KR (1) KR20260035942A (en)
CN (1) CN121794256A (en)
AR (1) AR133165A1 (en)
AU (1) AU2024290016A1 (en)
CO (1) CO2026000808A2 (en)
IL (1) IL325730A (en)
MX (1) MX2025015183A (en)
PE (1) PE20260501A1 (en)
TW (1) TW202517611A (en)
WO (1) WO2025008574A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1948597A1 (en) * 2005-10-21 2008-07-30 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
WO2015048570A2 (en) 2013-09-26 2015-04-02 Sanford-Burnham Medical Research Institute Ebi2 modulators
US11919895B2 (en) 2019-10-25 2024-03-05 Saint Louis University GPR183 antagonists for the treatment of pain
MX2024004722A (en) 2021-10-18 2024-07-24 Nanjing Immunophage Biotech Co Ltd Compounds and their uses as gpr183 inhibitors.

Also Published As

Publication number Publication date
AR133165A1 (en) 2025-09-03
TW202517611A (en) 2025-05-01
CN121794256A (en) 2026-04-03
EP4739656A1 (en) 2026-05-13
MX2025015183A (en) 2026-02-03
KR20260035942A (en) 2026-03-13
AU2024290016A1 (en) 2026-02-19
CO2026000808A2 (en) 2026-02-13
PE20260501A1 (en) 2026-02-27
WO2025008574A1 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
MX2020008559A (en) Heterocyclic compounds as kinase inhibitors.
PL2298743T3 (en) 5-membered heterocycle-based P38 kinase inhibitors
WO2005063766A3 (en) Bicyclic heterocyclic p-38 kinase inhibitors
MX2020010484A (en) Substituted heterocyclyl derivatives as cdk inhibitors.
IL288508A (en) N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2h-pyran-4-carboxamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
PH12015501958A1 (en) Processes and intermediates for making a jak inhibitor
MX2009011810A (en) Thiazoles and pyrazoles useful as kinase inhibitors.
MX2009012719A (en) Thiazoles and pyrazoles useful as kinase inhibitors.
ZA200706740B (en) Quinazolinone T-type calcium channel antagonists
TNSN05044A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
ATE534632T1 (en) THIAZOLES, IMIDAZOLES AND PYRAZOLES AS PROTEIN KINASE INHIBITORS
IL291665A (en) Inhibitors of receptor interacting protein kinase i for the treatment of disease
EP4051282A4 (en) Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (cdk7)
IL195900A0 (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
PL3972604T3 (en) BRUTON'S TYROSINE KINASE INHIBITOR FOR USE IN THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA
IL288924A (en) Casein kinase 1 inhibitors for use in the treatment of diseases related to dux4 expression such as muscular dystrophy and cancer
ZA202101118B (en) A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis
HUE069498T2 (en) Para-hydroquinone derivatives as vegf, tnf and/or il inhibitors for the treatment of neuroinflammatory diseases
AU2024290016A1 (en) 2-phenoxy-1-(4-(alkylsulfonyl)piperidin-1-yl)ethan-1-one and 3-phenyl-1-(4-(alkylsulfonyl)piperidin-1-yl)prop-2-en-1-one derivatives as gpr183 antagonists for the treatment of chronic pain
CA3296824A1 (en) 2-phenoxy-1-(4-(alkylsulfonyl)piperidin-1-yl)ethan-1-one and 3-phenyl-1-(4-(alkylsulfonyl)piperidin-1-yl)prop-2-en-1-one derivatives as gpr183 antagonists for the treatment of chronic pain
CL2004001430A1 (en) COMPOUNDS DERIVED FROM IMIDAZOL SUBSTITUTED WITH HETEROARILO; PREPARATION PROCESS; AND USE IN THE PREVENTION AND TREATMENT OF DISORDERS MEDIATED BY THE MGLUR5 RECEPTOR, ACUTE NEUROLOGICAL AND / OR CHRONIC DISORDERS AS SUCH AS ANXIETY AND CRONIC PAIN
DK1503764T3 (en) 5-HT4 receptor antagonists for the treatment of heart failure
HK40079169A (en) Inhibitors of receptor interacting protein kinase i for the treatment of disease
HK40087155A (en) Composition for use in the treatment of apol1-associated disease
TNSN05307A1 (en) 5-membered heterocycle-based p38 kinase inhibitors